Zydus Lifesciences

Pharmaceutical leader Zydus Lifesciences has introduced a biosimilar therapy targeting visual impairment, offering a cost-effective alternative to existing biologic treatments. The launch addresses critical needs in ophthalmology, particularly for conditions such as age-related macular degeneration and diabetic retinopathy, which affect millions globally. By providing clinically comparable efficacy at lower prices, Zydus aims to expand access to advanced therapies while reinforcing its presence in the high-growth biosimilars market.

Zydus Lifesciences has reached a $120 million settlement with Japan-based Astellas Pharma, bringing an end to a protracted patent litigation between the two pharmaceutical companies. The agreement resolves claims related to intellectual property rights over a key drug product and removes a significant legal overhang for both parties. The settlement provides clarity on commercialization pathways while averting prolonged courtroom proceedings. Industry analysts view the resolution as strategically prudent, enabling Zydus to recalibrate its pipeline priorities and capital allocation.

Zydus Lifesciences Ltd. reported a marginal yet steady rise in net profit for the third quarter, signaling resilience in its pharmaceutical operations amid a complex global healthcare environment. Profit for the period increased 1.81% year on year to Rs 1,042 crore, supported by consistent performance across key therapeutic segments and disciplined cost management. While revenue growth remained measured, the results underscored the company’s ability to protect margins and sustain cash flows.

Zydus Lifesciences Ltd has secured the Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (USFDA) for its novel therapeutic candidate, Desidustat, intended for the treatment of beta-thalassemia — a rare genetic blood disorder. The recognition marks a significant milestone in the company’s innovation journey, granting it several development incentives, including market exclusivity and tax benefits.

Zydus Lifesciences Ltd has achieved a significant milestone with regulatory approval from China’s National Medical Products Administration (NMPA) for its venlafaxine extended-release (ER) capsules in 75 mg and 150 mg strengths. The medication, used to treat major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (SAD), and panic disorder (PD), marks Zydus’s first approved product in China.

Zydus Lifesciences, a leading Indian pharmaceutical company, has entered into a strategic partnership with Netherlands-based Synthon to commercialize a novel multiple sclerosis (MS) therapy in the United States. The collaboration aims to accelerate patient access to the treatment while leveraging the combined strengths of both firms in research, development, and regulatory expertise.

Zydus Lifesciences has received final approval from the U.S. Food and Drug Administration (USFDA) to market a generic version of Ibrutinib, a drug widely used in the treatment of several blood cancers including mantle cell lymphoma and chronic lymphocytic leukemia. This regulatory clearance marks a significant addition to the company’s growing oncology portfolio and underscores its strategy to enhance access to high-value therapies in international markets.